With >100 pre-clinical candidates delivered, >500 patents granted, and >300 peer reviewed co-authored publications, our unique combination of integrated, multidisciplinary drug discovery expertise and unparalleled scope of capabilities in targets, platforms, and therapeutic areas allow us to deliver depth and breadth in science with data and insight you can trust.
A Humanized Lung Cancer In Vivo Platform for Immunotherapy Research
In immuno-oncology drug development, the translation of preclinical models in rodents to clinical reality is a challenge. This webcast will present a deep phenotypic characterization of 14 humanized NSCLC (non-small-cell lung cancer) patient-derived xenograft (PDX) models showing that PDX have distinct hot or cold phenotypes as an inherent model feature.
Beyond the Diagnosis: How Art is Changing the Face of Rare Disease
What happens when art meets advocacy? We sit down with Patricia Weltin, founder of Beyond the Diagnosis, to explore how portraiture is transforming awareness and empathy in the rare disease community.
How Well Do You Understand Off-target Liability?
Learn about the impact of off-target liability on drug discovery and therapeutic research in this Q&A with Sr. Principal Scientific Advisor and industry expert, Stan Spence.
WEBINAR: Maximize Safer, Targeted Biologic Development with Smarter NAMs-Based Off-Target Screening
This webinar showcases how the Retrogenix® platform empowers smarter, earlier decisions across biologic formats. You’ll also learn how this platform, recently accepted into the FDA’s ISTAND Pilot Program, aligns with evolving regulatory support for NAMs and the shift toward reduced animal use.
Watch the Replay